On 16 September 2026, Chinasoft International Limited (00354.HK) announced that its indirectly wholly-owned subsidiary Chinasoft Xi'an will acquire approximately 29.68% of Hangzhou Jingwei Information Technology Co., Ltd. (301390.SZ), namely 17,806,240 A shares, at RMB 53 per share, for a consideration of RMB 943,730,720.
On 16 September 2026, Quantgroup Holding Limited (02685.HK) entered into a placing agreement to place up to 48,529,412 shares at HK$ 3.40 per share, a discount of approximately 15.32% to the closing price of HK$ 4.015 on the same date, with net proceeds expected to be approximately HK$ 162.6 million.
On 16 September 2026, Beijing Geekplus Technology Co., Ltd. (02590.HK) announced that former shareholder Marcasite Gem Holdings Limited had sold 48,915,423 shares, representing approximately 4.78% of its issued shares, and no longer holds any shares after the disposal; the Company was not a party to the disposal.
On 16 September 2026, Fu Shou Yuan International Group Limited (01448.HK) announced the findings of an independent forensic investigation, in which the forensic accountant identified 69 suspicious transactions involving RMB 23,412,645, reduced to 64 transactions and RMB 22,767,433 after eliminating double counting; the Company's shares remain suspended from trading.
On 16 September 2026, Esprit Holdings Limited (00330.HK) announced that Kuang Qicheng has been appointed as an executive director and managing director, that Wright Bradley Stephen has been re-designated from acting chairman to chairman, and that Li Hui has resigned as an executive director, all with effect from the same date.
On 16 September 2026, Zhongguancun Science-Tech Leasing Co., Ltd. (01601.HK) announced that the Company, as lessor, entered into Finance Lease Agreement II with a lessee at a transfer consideration of RMB 100 million, with a lease term of 72 months and total lease payments of approximately RMB 118.3 million, and also entered into Finance Lease Agreement I on 15 September 2026 at a transfer consideration of RMB 50 million with total lease payments of approximately RMB 59.15 million; the two agreements are required to be aggregated and constitute discloseable transactions of the Company.
On 16 September 2026, AEON Stores (Hong Kong) Co., Limited (00984.HK) announced that its wholly-owned subsidiary AEON South China entered into a third supplemental agreement with the landlord in respect of the renewal agreement to reduce the unit rental price of the premises, cutting the total rent payable for the remaining lease term (excluding taxes) from approximately RMB 495 million to approximately RMB 359 million.
On 16 September 2026, Fujian Haixi Pharmaceuticals Co., Ltd. (02637.HK) announced that the 24-week treatment data observation of the China Phase I clinical study of its self-developed candidate drug molecule HX9428 for the treatment of neovascular age-related macular degeneration (nAMD) has been completed, while the Phase II dose expansion study is ongoing with interim data obtained; among the 13 patients who completed 24 weeks of treatment in Phase I, BCVA improved by an average of 5.2 letters from baseline and CST decreased by an average of 73.3 μm.
On 16 September 2026, China Merchants Land Limited (00978.HK) announced that its indirect non-wholly-owned subsidiary Foshan China Merchants Baohua Real Estate Co., Ltd. entered into an agreement for the resumption of state-owned land use rights in respect of a land plot in Nanhai District, Foshan City with the Land Reserve Centre of Nanhai District and the Guicheng Subdistrict Office, for aggregate cash compensation of RMB 569,067,951.00.
On 16 September 2026, SR Medical Technology Company Limited (00108.HK) announced that Mr. Shao Jiyou has been nominated as an executive director with effect from 16 September 2026, for an initial fixed term of three years with an annual director's remuneration of HKD 540,000.
On 16 September 2026, CSPC PHARMA (01093.HK) announced that the Phase II clinical trial (SYH2069-003) of SYH2069 injection, developed by the Group, for the treatment of adult type 2 diabetes has formally commenced at the first study site in China.
On 16 September 2026, PATEO (02889.HK) announced that Mr. Liang Chen, vice president of the Company's procurement centre, acquired an aggregate of 27,740 H shares of the Company on the open market using his own funds on 16 September 2026, representing approximately 0.017% of the total issued shares, for an aggregate consideration of approximately RMB 2 million at an average price of approximately HKD 84.28 per share.
On 16 September 2026, CHINA RUYI (00136.HK) published an inside information announcement disclosing the Group's AI strategy and its application across business segments, and announcing that its subsidiary Virtual Cinema Culture Limited entered into a cloud service agreement with an independent third party, Superpower X AI (Singapore) Technology Pte. Ltd., with an initial service term of five years.
On 16 September 2026, DIT GROUP (00726.HK) announced that Mr. Chen Aiguo has been appointed as an executive director of the Company with effect from 16 September 2026; he has over 18 years of experience in real estate enterprise management and served as an executive director of Central China Management Company Limited from January 2023 to July 2025.
On 16 September 2026, SUN HING PRINT (01975.HK) issued a positive profit alert stating that, compared with a loss of approximately HKD 88.6 million for the year ended 30 June 2025, the Group is expected to record a profit for the year of between approximately HKD 10.0 million and HKD 20.0 million for the year ended 30 June 2026.
On 16 September 2026, HANSOH PHARMA (03692.HK) announced that HS-20197 for injection, a Class 1 innovative drug independently developed by the Group, obtained a drug clinical trial approval notice issued by the National Medical Products Administration on 11 September 2026, for the conduct of clinical trials in "advanced solid tumours".
